As a pilot and first-in-human study, we focused on evaluating the feasibility of in vivo PET/CT imaging of CCR2 in AAAs without stratifying patients into medical observation versus surgical treatment groups. Here, CCR2 is linked to achalasia-alacrima syndrome.